Compare BTMD & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTMD | MDAI |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | 65 |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.8M | 53.8M |
| IPO Year | 2021 | N/A |
| Metric | BTMD | MDAI |
|---|---|---|
| Price | $1.53 | $1.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.83 | ★ $3.00 |
| AVG Volume (30 Days) | ★ 201.8K | 160.6K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 722.22 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $192,219,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $6.58 | $23.50 |
| P/E Ratio | $27.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $1.18 |
| 52 Week High | $3.61 | $2.97 |
| Indicator | BTMD | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 31.17 | 48.57 |
| Support Level | $1.35 | $1.62 |
| Resistance Level | $1.69 | $1.77 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 8.49 | 80.00 |
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.